[80] The trial reported cumulative occurrence of major adverse cardiovascular events, a primary end-point event of the trial, for 569 of the 8803 patients in the semaglutide group, which were 6.5% of the participants, and for 701 of the 8801 patients in the placebo group, which were 8% of the participants, showing relative 18.8% less major adverse cardiovascular events, such as death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke, occurring for participants who had received semaglutide in the trial relative to those who had received placebo over the course of around 48 months, or 34.213.7 months, which was the mean (SD) total duration of the participants in either group's exposure to the placebo or semaglutide during the trial
Ethics declarations Conflict of Interest James Amamoo: Employee of Novo Nordisk Inc
"Denmark's economy runs on Novo
Food & Drug Administration (FDA) Wegovy (Semaglutide) Prescribing Information (Official Dosing): National Library of Medicine Off-Label Use of Medications: Institute for Safe Medication Practices (ISMP) Patient Safety and Medication Errors:
